Avillion Development 1

Avillion Development 1 is a specialized drug development entity operating under the parent company Avillion LLP. The company utilizes an innovative co-development model where it partners with large pharmaceutical companies to fund and execute late-stage clinical trials. This specific entity was responsible for the successful Phase 3 BFORE trial of Pfizer's Bosulif (bosutinib), which led to its regulatory approval for the first-line treatment of chronic myeloid leukemia. By assuming the financial and operational risks of clinical development, Avillion Development 1 enables its partners to advance pipeline assets without immediate capital expenditure. The company is backed by prominent life science investors, including Abingworth and Blackstone Life Sciences. Its business model focuses on high-potential assets that require robust clinical validation for expanded indications or primary approvals.